Deborah Caserta-Brunson, MD
Internal Medicine · Milford, CTNPI 1659392363
Payments from drug & device makers
Across 697 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- GSK$976
- Amgen$840
- plus $6K from 31 others
What the payments were for
- Food & beverage$12,802100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $1,494 |
| Novo Nordisk | 76 | $1,484 |
| Lilly USA, LLC | 61 | $1,118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $1,008 |
| GSK | 50 | $976 |
| Amgen(2 entities) | 42 | $840 |
| Boehringer Ingelheim | 40 | $737 |
| Arbor Pharmaceuticals, Inc. | 51 | $723 |
| Merck | 38 | $689 |
| AstraZeneca | 34 | $600 |
| Exact Sciences | 22 | $464 |
| Axsome Therapeutics, Inc. | 15 | $396 |
| Eisai Inc. | 20 | $282 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $273 |
| Amarin Pharma, Inc. | 13 | $246 |
| Johnson & Johnson | 14 | $217 |
| Pfizer | 8 | $159 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $134 |
| Mylan Specialty L.p. | 7 | $126 |
| Currax Pharmaceuticals LLC | 7 | $110 |
| Adlon Therapeutics L.p. | 5 | $104 |
| Radius Health, Inc. | 4 | $81 |
| Novartis | 3 | $59 |
| Azurity Pharmaceuticals, Inc. | 3 | $57 |
| Almatica Pharma LLC | 3 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $45 |
| Vistapharm, Inc. | 3 | $42 |
| Intra-sana Laboratories | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $38 |
| Mission Pharmacal Company | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Bayer | 1 | $28 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $15 |
How this compares
$12,802 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $43,629 |
| JardianceEmpagliflozin | 42 | $37,524 |
| JanuviaSitagliptin Phosphate | 21 | $28,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,198 |
| SynthroidLevothyroxine Sodium | 65 | $5,006 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $3,576 |
| Levothyroxine Sodium | 278 | $3,237 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,696 |
| Rosuvastatin Calcium | 117 | $1,893 |
| FenofibrateFenofibrate Nanocrystallized | 46 | $1,412 |
| Lisinopril | 174 | $1,280 |
| Atorvastatin Calcium | 158 | $1,219 |
| Valsartan | 38 | $1,138 |
| Nebivolol Hcl | 13 | $1,047 |
| Desloratadine | 11 | $886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,484 | $43,62936 claims |
| Boehringer IngelheimJardiance | $737 | $37,52442 claims |
| MerckJanuvia | $689 | $28,48621 claims |
| GSKAnoro Ellipta | $976 | $6,19813 claims |
| AbbVieSynthroid | $1,494 | $5,00665 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $38 | $3,237278 claims |
| Almatica Pharma LLCSertraline Hcl | $49 | $35433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Milford
- Steven SaundersMilford$49K
- Gary SpectorMilford$32K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.